Guerbet (0ELV)
London Exchange · UK · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 5.820 |
|---|---|
| 52-week range | 5.820 – 18.130 |
| Return, 1 month / 3 months | −19.7% / −35.8% |
| Return, 1 year / 3 years | −60.8% / −64.0% |
| Trend | Below its 200-day average |
| RSI (14) | 11 |
| Volatility (1 year) | 66.5% |
| Worst drawdown (1 year) | -70.3% |
| Average daily value traded | 0.00M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Guerbet is a pharmaceutical company focused on medical imaging. It develops and supplies contrast agents used in X-ray, magnetic resonance imaging and ultrasound examinations, along with injection systems and related products that help clinicians obtain clearer images of the body. Its customers are hospitals, imaging centres and healthcare professionals who use these products in diagnostic procedures. The company is based in France and serves medical imaging markets in many countries around the world.
Guerbet trades under the code 0ELV on the London Exchange in UK, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 6 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Guerbet (0ELV) trades on the London Exchange in UK. It last closed at EUR 5.820 on 22 October 2026.
Its price-based Market X-Ray is 7 out of 100 (a weak price profile), ranking 3,744 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 60.8% and over the last three months it fell 35.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 4 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -46.5% | ||
| From 52-week high | -67.8% | ||
| Momentum | 6 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -35.8% | ||
| 6-month return | -41.9% | ||
| 12-month return, skipping the last month | -51.1% | ||
| Stability (higher is calmer) | 12 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 66.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -70.3% | ||
| Liquidity | 5 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.00M EUR | ||
| Zero-volume days | 16.7% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 3 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −7.9% |
|---|---|
| 1 month | −19.7% |
| 3 months | −35.8% |
| 6 months | −41.9% |
| 1 year | −60.8% |
| 3 years | −64.0% |
| 5 years | −84.5% |
Signals
| 50-day / 200-day average | 7.515 / 10.888 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.106 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 1 Jul 2024 | EUR 0.5000 |
| 29 Jun 2023 | EUR 0.5000 |
| 29 Jun 2022 | EUR 0.8500 |
| 29 Jun 2021 | EUR 0.7000 |
| 30 Jun 2020 | EUR 0.7000 |
| 3 Jun 2019 | EUR 0.8500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.